Clinical Trials Logo

Atypical Meningioma clinical trials

View clinical trials related to Atypical Meningioma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04761653 Recruiting - Atypical Meningioma Clinical Trials

Study of the Inflammatory Microenvironment in Atypical Meningiomas

Start date: January 1, 2021
Phase:
Study type: Observational

Atypical meningiomas represent 15% of meningiomas. They present a high rate of recurrence, and therapeutic strategies are limited. There is a need for novel treatment strategies, such as immuotherapy. This is a retrospective study including 84 patients with primary diagnosis of atypical meningiomas. The presence of T cells (CD4, CD8, Treg and memory T cells) and mature dendritic cells will be quantified on whole tissue sections stained by immunohistochemistry (CD4, CD8, FOXP3, CD45RO and CD208). This could allow us to identify novel biomarkers for survival, and facilitate the selection of patients who may benefit from immunotherapeutic modalities.

NCT ID: NCT04541082 Recruiting - Glioblastoma Clinical Trials

Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

Start date: October 26, 2020
Phase: Phase 1
Study type: Interventional

The primary objective of this Phase 1, open-label, dose-escalation, and exploratory study is to evaluate the safety and tolerability profile (establish the maximum-tolerated dose) and evaluate the occurrence of dose-limiting toxicities (DLTs) following single weekly or multiple-day weekly dose regimens of single-agent, oral ONC206 in patients with recurrent, primary central nervous system (CNS) neoplasms.

NCT ID: NCT03016091 Recruiting - Clinical trials for Anaplastic Meningioma

A Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma

Start date: February 20, 2018
Phase: Phase 2
Study type: Interventional

A Phase II, Open-label, Single Arm Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma

NCT ID: NCT02973256 Recruiting - Clinical trials for Anaplastic Meningioma

Oncological Care for Patients With Meningioma

ATYPICMENING
Start date: January 1, 2019
Phase:
Study type: Observational

Meningiomas with malignant components include grade II meningiomas (GIIM, the most common ones) and grade III meningiomas (GIIIM). They represent 5-35% of all meningiomas. Histological diagnosis of GIIM criteria were changed in 2007 and might be viewed by some as being quite subjective. "Standards of care" and consensus do not exist for GIIM, particularly in regards to performing, or not, radiotherapy after surgery. One other limitation in the literature is lack of data on health-related quality of life (HRQoL). Clinical trials for GIIM are very difficult to conduct. No results have been made available. Here, we propose to study clinical, pathological, radiological and therapeutic factors of an exhaustive population of GIIM and GIIIM patients, at national level. The main objective (for GIIM) is to assess the impact of postoperative radiotherapy, or the absence of postoperative radiotherapy, on overall survival and on quality of life

NCT ID: NCT02847559 Recruiting - Clinical trials for Recurrent Meningioma

Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

Start date: August 2016
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to determine the effects bevacizumab (the study drug) combined with Optune (the study device) tumor treatment field therapy has on meningiomas. Bevacizumab is considered investigational because the US Food and Drug Administration (FDA) has not approved its use for the treatment of meningiomas. The study drug is a medication that blocks the growth of new blood vessels. It is thought that the study drug may interfere with the growth of new blood vessels and therefore might stop tumor growth, and possibly shrink the tumor by keeping it from receiving nutrients and oxygen supplied by the blood vessels. Optune is also considered investigational because the US FDA has not approved its use for the treatment of meningiomas. Optune is a device that the patient will wear and use for at least 18 hours of each day. It delivers alternating electrical current to the patient's brain tumor and by doing so interrupts a process called mitosis. Mitosis needs to occur in order for cell division to occur and allows tumors to grow. By slowing this process, we hypothesize that meningioma growth may also be slowed.